Clinical trials are needed in order to be able to develop new therapies for significant conditions such as cancer. Over time, it has been proven that these trials, with the participation of a large number of patients, are the only way to progress in the treatment of conditions of such significance considering the severity and number of individuals affected, and the implementation of the results of these studies in current medical practice saves millions of lives worldwide every year.
National, European and International clinical trials are conducted according to very strict medical and legal rules and regulations, in order to minimize any serious or even fatal adverse reactions.
Amethyst is at the forefront of medical research in Europe. On this page you can check the medical trials led or participated by Amethyst centres across Europe.
CS001P3: Multi-center Study of the Effects of Leukocyte Interleukin
Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection (Multikine) plus Standard of Care (Surgery+ Radiotherapy or Surgery + Concurrent Chemoradiotherapy) in Subject with Advance Primary Squamous Cell Carcinoma of Oral Cavity/Soft Palate versus Standard of Care OnlyCEL-SCI Corporation, Protocol number: CS001P3,
Prospectiv interventional Trial - Combined chemo-radiotherapy Treatment in cervical cancer- Embrace II.
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).
This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves major pathological response and event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review (BICR).
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).
A phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant therapy for Participants with Resectable IIB or IIIA non-small Cell Lung Cancer(NSCLC) (KEYNOTE-671)
This is a Phase II Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer.
A phase 3 randomized, placebo-controlled double-blind study of JNJ-56021927 in combination with a GNRH Agonist versus GNRH Agonist plus placebo in subjects with high-risk localized or locally advanced prostate cancer and treated with primary radiation therapy The purpose of this study is to determine if JNJ-56021927 plus gonadotropin releasing hormone(GnRH) in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival.